HaloVax, LLC. is leveraging the existing Voltron Therapeutics platform for a self-assembling vaccine (SAV) that improves cell mediated responses to combat COVID-19. Technology licensed from the Vaccine & Immunotherapy Center at the Massachusetts General Hospital.